PROK
ProKidney Corp.2.2000
+0.1200+5.77%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
661.84MP/E (TTM)
-Basic EPS (TTM)
-0.55Dividend Yield
0%Recent Filings
10-K
FY2025 results
ProKidney Corp., a late-clinical-stage biotech, reported FY2025 ended December 31, 2025 with no revenue as no products are approved for sale, consistent with its pre-commercial status focused on rilparencel cell therapy for CKD patients. Completed REGEN-007 Phase 2 trial in May 2025, showing 78% eGFR slope improvement from -5.8 to -1.3 mL/min/1.73m²/year in Group 1 (derived). Ongoing Phase 3 PROACT 1 targets topline surrogate endpoint data Q2 2027. Q4 saw property sale agreement for $19.05M industrial facility in Colfax, NC, signed October 2025. Cash burn continues; needs capital. Clinical trial delays threaten momentum.
8-K
ProKidney 2025 results, strong cash
ProKidney reported full-year 2025 results on March 18, 2026, with $270.0 million in cash funding operations into mid-2027, down from $358.3 million in 2024 amid $151.6 million net loss before noncontrolling interest. Phase 3 PROACT 1 enrollment tracks for mid-2026 completion and Q2 2027 eGFR slope readout after FDA alignment on accelerated approval. Cash burn eased. Risks include trial delays.
8-K
PROACT 1 enrollment upsized
ProKidney updated its investor presentation, raising Phase 3 PROACT 1 target enrollment to ~470 subjects while holding eGFR slope readout for Q2 2027 and confirmatory endpoint for H2 2029. Statistical powering stays intact despite the hike. Cash funds operations into mid-2027. Trial risks loom large.
8-K
Updated presentation signals PROACT momentum
ProKidney updated its investor presentation on January 12, 2026, highlighting Phase 3 PROACT 1 enrollment momentum for rilparencel, with pivotal eGFR slope topline data expected Q2 2027. Cash of $272M funds operations into mid-2027. Phase 2 REGEN-007 stabilized kidney function, slashing eGFR decline 78% to -1.27 mL/min/1.73m²/year. Forward-looking claims carry clinical risks.
10-Q
Q3 FY2025 results
ProKidney posted Q3 revenue of $217K from facility leases, up from zero, yet operating loss narrowed 21% y/y to $38.5M as R&D expenses dropped 14% to $26.8M and G&A fell 33% to $11.9M. Diluted EPS improved to $(0.12) from $(0.14), aligning with 135M weighted shares. Cash burn eased, with operating cash use at $87.6M YTD versus $102.2M prior year; quarter-end cash plus marketable securities stood at $271.7M, no debt. Expenses trimmed sharply. Regulatory hurdles shadow progress.
CLCS
Cell Source, Inc.
0.45+0.08
FBLG
FibroBiologics, Inc.
0.24-0.02
NBTX
Nanobiotix S.A.
22.32+0.18
PKTX
ProtoKinetix, Inc.
0.00+0.00
PLX
Protalix BioTherapeutics, Inc.
1.81+0.07
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
REVB
Revelation Biosciences, Inc.
0.98+0.02
TARA
Protara Therapeutics, Inc.
5.42-0.08
UNCY
Unicycive Therapeutics, Inc.
5.88+0.00